Alcon to Acquire Exclusive US Commercialization Rights to Novartis’ Simbrinza
Shots: Novartis to receive $355M following the closure of acquisition, which is expected to occur in Q2’21. The acquisition expands existing Alcon’s ophthalmic portfolio and […]